Interestingly, in a case of an individual with juvenile parkinsonism due to homozygous deletion of exon 3 in the parkin gene after STN-DBS, there was significant motor improvement and a reduction in the levodopa-equivalent daily dose medication by 66%, as well as complete resolution of severe dyskinesias [54]. This evidence concerns the gene PRKN and Dyskinesia.